The Southwest Oncology Group is an adult, multi-disease, multi-modality clinical cancer research organization with 35 Member Institutions, 29 Community Clinical Oncology Program (CCOP) institutions, including 7 Minority-Based CCOPs, 27 Urologic Cancer Outreach Program (UCOP) members, and a network of 1,036 Affiliate Program investigators at 189 offices and hospitals, and 12 institutions participating in the CTEP Minority program. A special emphasis of the Group is managed by the renamed Committee on Special Populations, established in 1992. The committee's research and education agenda has broadened to include: women (or men), older cancer patients, cancer survivors, and raciallethnic minority groups (African-American, Hispanic Americans and Asian American Pacific Islanders). Involving patient advocates in Group activities is an important role of this committee. The committee report details the cross-committee research and publications. The moral and ethical conduct of clinical research by the group members is emphasized by ethics training, the conflict of interest policy, affirmation of integrity and data and safety monitoring. In addition to the presentation of correlative science activities tied to tumor banks related to disease committees, we propose a Correlative Sciences Committee, which will provide oversight of science and quality assurance of assay technology across the six Disease Committee correlative science programs in the Group. There are three new initiatives in this application. Two new adult medical oncology intergroup proposals, one dealing with advanced gynecologic cancer, the U.S. Gynecology Intergroup, and the second dealing with sarcomas, The U.S.ICanada Sarcoma Intergroup. The third is the Early Therapeutics Committee, which will take advantage of the 10 institutions in the Group who hold Phase I NCI funded U-01s. This will be possible with the new Web-Based, Multi-User Phase I Monitoring System implemented by our Statistical Center. PERFORMANCE Orqanization City State CTRC Foundation San Antonio TX Southwest Oncology Group Operations Office San Antonio TX (the remaining

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA032102-28S3
Application #
7498258
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1981-07-16
Project End
2009-12-31
Budget Start
2007-04-05
Budget End
2007-12-31
Support Year
28
Fiscal Year
2007
Total Cost
$316,222
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92
Moots, Paul L; O'Neill, Anne; Londer, Harold et al. (2018) Preradiation Chemotherapy for Adult High-risk Medulloblastoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4397). Am J Clin Oncol 41:588-594
Ni, Haiwen; Shirazi, Fazal; Baladandayuthapani, Veerabhadran et al. (2018) Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. Clin Cancer Res 24:6408-6420
Gravis, Gwenaelle; Boher, Jean-Marie; Chen, Yu-Hui et al. (2018) Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol 73:847-855
Francis, Prudence A; Pagani, Olivia; Fleming, Gini F et al. (2018) Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med 379:122-137
Manasanch, Elisabet E; Orlowski, Robert Z (2017) Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol 14:417-433
Regan, M M; Walley, B A; Francis, P A et al. (2017) Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. Ann Oncol 28:2225-2232
Agarwala, Sanjiv S; Lee, Sandra J; Yip, Waiki et al. (2017) Phase III Randomized Study of 4 Weeks of High-Dose Interferon-?-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Gro J Clin Oncol 35:885-892
Lee, Hans C; Wang, Hua; Baladandayuthapani, Veerabhadran et al. (2017) RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma. Br J Haematol 177:80-94
Sala Torra, Olga; Othus, Megan; Williamson, David W et al. (2017) Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients. Biol Blood Marrow Transplant 23:691-696

Showing the most recent 10 out of 742 publications